Reply to: Marketing pitches of ‘magic mushrooms’ and ‘psychedelics’ mask that psychotomimetics use exposes those vulnerable to serious adverse effects
Emma Morton, Kimberly Sakai, Amir Ashtari, M. Pleet, E. Michalak, J. Woolley
Journal of Psychopharmacology July 1, 2023 DOI: 10.1177/02698811231169641a via Semantic Scholar
Study at a glance
| Characteristics | Peer reviewed |
|---|---|
| Keywords | Medicine |
Abstract
Braillon A (2011) The many moral responsibilities of independent datamonitoring committees. Am J Bioeth 11: 16–17. Council for International Organizations of Medical Sciences (1999) Guidelines for preparing core clinical-safety information on drugs second edition – Report of CIOMS working groups III and V. Geneva: Council for International Organizations of Medical Sciences. Huxley A (1961) US State Department-sponsored speech to the Tavistock Group. California Medical School. Morton E, Sakai K, Ashtari A, et al. (2023) Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of 'magic mushroom' consumption. J Psychopharmacol 37: 49–60. Naudet F, Fried EI, Cosgrove L, et al. (2022) Psychedelic drugs: More emphasis on safety issues. Nature 611: 449. Tanne JH (2004). Humphry Osmond. BMJ 328: 713.